You are here

P&T April 2017


Rhetoric Meets Reality With PPACA Replacement

As legislation is drafted to replace Obamacare, pharmaceutical issues—including controlling drug prices, expanding or contracting drug access, and incentivizing the development of generic drugs—are expected to be at the forefront of debate.

The authors explore efficacy and safety outcomes in multiple degrees of renal impairment when using FDA-approved dosing regimens for enoxaparin and find that a more multitiered dosing strategy appears to be needed.

Using a retrospective chart review, the authors compare the effectiveness of these two methods of administration in intensive care unit patients with septic shock.

While an educational video led to improvements in short-term knowledge, patients did not retain their understanding at one month, suggesting that future studies should evaluate other strategies to improve long-term retention of knowledge.

Pipeline Plus

We present immunotherapies, biosimilars, and molecular-targeted agents in late-stage development for patients with advanced colorectal cancer.

Meeting Highlights

One clinician’s controversial position against routine use of opioids for chronic pain.

Meeting Highlights

We focus on liver-directed cancer therapy and the role of yittrium-90, as well as one clinician’s controversial position against routine use of opioids for chronic pain.


Medication Errors

Twelve persistent safety gaffes that need resolution

Prescription: Washington

FDA pleases no one with final guidance on biological and biosimilar naming

Approvals, new indications, regulatory activities, and more

Abuse-deterrent hydrocodone bitartrate (Vantrela ER) for long-term opioid treatment; etelcalcetide (Parsabiv) for secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis; and deflazacort (Emflaza) for Duchenne muscular dystrophy

Drug Forecast

Flibanserin (Addyi) for female sexual interest/arousal disorder in premenopausal women